We would like to congratulate Dr. Jerome Breslin, who has been elected as President-Elect of the Microcirculatory Society. The link to the Microcirculatory Society’s website is listed here for reference: https://www.microcirc.org/ . Dr. Breslin will lead the Microcirculatory Society in its mission to “actively encourage and promote all forms of innovative research and teaching, leading to an increase in understanding of microcirculatory function in health and disease.” This is a prestigious honor and we are very proud to have Dr. Breslin on our team. Congratulations!
Dr. Hana Totary-Jain has been selected as the winner of the 2020 Alan T. Hirsch, MD Mid-Career Award in Vascular Medicine. Dr. Totary-Jain is an Associate Professor in the Department of Molecular Pharmacology and Physiology and her lab focuses on non-coding RNAs and their regulatory role in cardiovascular diseases. The award was presented during the AHA Vascular Discovery: From Genes to Medicine Scientific Sessions 2020.
The title of her talk: "Design and delivery of microRNA switches to treat cardiovascular diseases".Description: 3D confocal image from whole mount of mouse wire-injured femoral arteries 48 hours after a single intravenous injection of niRFP mRNA-p5RHH nanoparticle.
Professor, USF Health Heart Institute
Vice Dean for Research, Morsani College of Medicine
Associate Vice President for Research, USF Health
Professor of Internal Medicine
Associate Professor, USF Health Heart Institute
The short third intracellular loop and cytoplasmic tail of bitter taste receptors provide functionally relevant GRK phosphorylation sites in TAS2R14.
Bitter taste receptors (TAS2Rs) are recognized asbeing expressed on multiple cell types and organs, includinghuman airway smooth muscle (HASM) cells, where agonistspromote significant relaxation to constrictive stimuli. Thus, theHASM TAS2Rs have been targeted as novel bronchodilators forthe treatment of asthma and other obstructive lung diseases. These studies revealed critical structural requirements for favorable potencies andefficacies for a potentialfirst-in-class bronchodilator targeting TAS2R5 of the airway.